PE-backed management buyout at Synexus

By Gareth Macdonald

- Last updated on GMT

PE-backed management buyout at Synexus

Related tags Synexus

Synexus has been bought by its management in a private equity backed deal that sees Lyceum Capital relinquish control of the trial recruitment specialist.

The deal – terms of which have not been disclosed – will facilitate global expansion according to Synexus, which suggested it may invest in research centres in the US, Asia and South America.

UK-based fund Lyceum Capital bought Synexus in 2007 for £18m ($27m) in a deal that saw it leave London's AIM just two years after it joined to raise cash for acquisitions.

Under Lyceum's ovnership Synexus's expansion continued. The patient recruitment firm increased its 13-strong network of research centers to 25 sites in eight countries through acquisitions.

Sites bought under Lyceum included facilities in the UK, Germany, Romania, Poland and Bulgaria.

Most recently​, Synexus bought a fourth site in South Africa citing customer demand for more trial capacity in Africa.


CEO Christophe Berthoux said Synexus’ needs to need to continue to invest in "infrastructure and operations so that we carry on providing clients the best solution delivering thousands of patients and providing excellent quality data​."

The takeover - which was brokered by Fairmount Partners - is being supported by LDC, the private equity arm of the Lloyds Banking Group, whose director Ged Gould will sit on Synexus board.

Gould echoed Berthoux’s comments about expansion.

We are eager to further support the business break into new markets as it targets opportunities in the US, South America and Asia.”

According to financials disclosed after the buyout was announced, Synexus generated revenue of $63m in 2014, which it said was a 140% increase on that recorded in 2011. The firm also said it has $216m worth of orders, up from the $193m in saw four years ago.

Reports in the UK press​ suggest Synexus management and LDC paid £83m for the services firm.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us